NO332182B1 - 2-alkynyl- og 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidin-adenosin A2a-reseptorantagonist, anvendelse derav for fremstilling av et medikament, og farmasoytisk preparat omfattende forbindelsen - Google Patents

2-alkynyl- og 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidin-adenosin A2a-reseptorantagonist, anvendelse derav for fremstilling av et medikament, og farmasoytisk preparat omfattende forbindelsen Download PDF

Info

Publication number
NO332182B1
NO332182B1 NO20055510A NO20055510A NO332182B1 NO 332182 B1 NO332182 B1 NO 332182B1 NO 20055510 A NO20055510 A NO 20055510A NO 20055510 A NO20055510 A NO 20055510A NO 332182 B1 NO332182 B1 NO 332182B1
Authority
NO
Norway
Prior art keywords
alkyl
mmol
preparation
mixture
product
Prior art date
Application number
NO20055510A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055510D0 (no
NO20055510L (no
Inventor
Bernard R Neustadt
Samuel Chackalamannil
Andrew W Stamford
Craig D Boyle
Jinsong Hao
Hong Liu
Unmesh G Shah
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20055510D0 publication Critical patent/NO20055510D0/no
Publication of NO20055510L publication Critical patent/NO20055510L/no
Publication of NO332182B1 publication Critical patent/NO332182B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20055510A 2003-04-23 2005-11-22 2-alkynyl- og 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidin-adenosin A2a-reseptorantagonist, anvendelse derav for fremstilling av et medikament, og farmasoytisk preparat omfattende forbindelsen NO332182B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46484003P 2003-04-23 2003-04-23
PCT/US2004/012471 WO2004094431A2 (en) 2003-04-23 2004-04-21 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists

Publications (3)

Publication Number Publication Date
NO20055510D0 NO20055510D0 (no) 2005-11-22
NO20055510L NO20055510L (no) 2006-01-20
NO332182B1 true NO332182B1 (no) 2012-07-23

Family

ID=33310963

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055510A NO332182B1 (no) 2003-04-23 2005-11-22 2-alkynyl- og 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidin-adenosin A2a-reseptorantagonist, anvendelse derav for fremstilling av et medikament, og farmasoytisk preparat omfattende forbindelsen

Country Status (32)

Country Link
US (2) US6897217B2 (zh)
EP (1) EP1622912B1 (zh)
JP (2) JP4527712B2 (zh)
KR (1) KR100831107B1 (zh)
CN (1) CN100503609C (zh)
AR (1) AR044041A1 (zh)
AT (1) ATE432282T1 (zh)
AU (1) AU2004233334B2 (zh)
BR (1) BRPI0409787B8 (zh)
CA (1) CA2522813C (zh)
CL (1) CL2004000847A1 (zh)
CO (1) CO5700766A2 (zh)
CY (1) CY1109263T1 (zh)
DE (1) DE602004021250D1 (zh)
DK (1) DK1622912T3 (zh)
EC (1) ECSP056115A (zh)
ES (1) ES2326270T3 (zh)
HK (1) HK1085466A1 (zh)
HR (1) HRP20090394T1 (zh)
IL (1) IL171567A (zh)
MX (1) MXPA05011366A (zh)
MY (1) MY139344A (zh)
NO (1) NO332182B1 (zh)
NZ (1) NZ542823A (zh)
PE (1) PE20050141A1 (zh)
PL (2) PL1622912T3 (zh)
PT (1) PT1622912E (zh)
RU (1) RU2373210C2 (zh)
SI (1) SI1622912T1 (zh)
TW (2) TWI355381B (zh)
WO (1) WO2004094431A2 (zh)
ZA (1) ZA200508489B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7313588B1 (en) * 2000-07-13 2007-12-25 Biap Systems, Inc. Locally executing software agent for retrieving remote content and method for creation and use of the agent
IL161716A0 (en) * 2001-11-30 2004-09-27 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
MXPA05006790A (es) * 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
JP4527712B2 (ja) * 2003-04-23 2010-08-18 シェーリング コーポレイション 2−アルキニル−ピラゾロ−[4,3−e]−1,2,4−トリアゾロ−[1,5−c]−ピリミジンアデノシンA2aレセプターアンタゴニストおよび2−アルケニル−ピラゾロ−[4,3−e]−1,2,4−トリアゾロ−[1,5−c]−ピリミジンアデノシンA2aレセプターアンタゴニスト
ES2342082T3 (es) * 2004-04-21 2010-07-01 Schering Corporation Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.
ES2385702T3 (es) * 2005-06-07 2012-07-30 Kyowa Hakko Kirin Co., Ltd. Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad
CN101312978A (zh) 2005-09-19 2008-11-26 先灵公司 作为腺苷A2a受体拮抗剂的2-杂芳基-吡唑并-[4,3-e]-1,2,4-三唑并-[1,5-c]-嘧啶
AR056080A1 (es) * 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
EP2262811B1 (en) * 2008-03-04 2016-04-27 Merck Sharp & Dohme Corp. 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e]-1,2,4-triazolo [4,3-c]pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
US8501997B2 (en) 2008-08-25 2013-08-06 Air Products And Chemicals, Inc. Curing agent for low temperature cure applications
US8512594B2 (en) * 2008-08-25 2013-08-20 Air Products And Chemicals, Inc. Curing agent of N,N′-dimethyl-meta-xylylenediamine and multifunctional amin(s)
RS53416B (en) 2009-03-10 2014-12-31 Takeda Pharmaceutical Company Limited BENZOFURAN DERIVATIVES
WO2011017299A2 (en) * 2009-08-07 2011-02-10 Schering Corporation PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
CN104870421A (zh) * 2011-12-27 2015-08-26 比皮艾思药物研发有限公司 用于预防或治疗als的苯基氨基甲酸酯化合物
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
BR112015020998B1 (pt) * 2013-03-14 2022-10-18 Galapagos Nv Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
CN114667287A (zh) * 2019-07-17 2022-06-24 泰昂治疗公司 腺苷a2a受体拮抗剂及其用途
CN115160120A (zh) * 2022-08-02 2022-10-11 乐威医药(江苏)股份有限公司 一种多烷氧基芳香酮的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US785906A (en) * 1904-12-06 1905-03-28 Albert P Mcbride Casing packer and shoe for gas or oil wells.
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
EP0666079B1 (en) * 1993-07-27 2001-11-07 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
DE19826843A1 (de) * 1998-06-16 1999-12-23 Boehringer Ingelheim Pharma Neue Imidazotriazolopyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT1283839E (pt) * 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
CN1491227A (zh) * 2001-02-05 2004-04-21 株式会社大V制药工厂 三唑并喹唑啉和吡唑并三唑并嘧啶衍生物、医药组合物、腺苷 a 3受体亲和剂、降眼压剂、预防和治疗青光眼的制剂及降低眼压的方法
AR037243A1 (es) 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
MXPA05006790A (es) 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
JP4527712B2 (ja) * 2003-04-23 2010-08-18 シェーリング コーポレイション 2−アルキニル−ピラゾロ−[4,3−e]−1,2,4−トリアゾロ−[1,5−c]−ピリミジンアデノシンA2aレセプターアンタゴニストおよび2−アルケニル−ピラゾロ−[4,3−e]−1,2,4−トリアゾロ−[1,5−c]−ピリミジンアデノシンA2aレセプターアンタゴニスト

Also Published As

Publication number Publication date
EP1622912A2 (en) 2006-02-08
DK1622912T3 (da) 2009-09-07
MY139344A (en) 2009-09-30
CO5700766A2 (es) 2006-11-30
US20050222164A1 (en) 2005-10-06
SI1622912T1 (sl) 2009-10-31
CA2522813C (en) 2009-09-08
PL1622912T3 (pl) 2009-11-30
NZ542823A (en) 2009-03-31
MXPA05011366A (es) 2005-11-28
JP2010059178A (ja) 2010-03-18
WO2004094431A3 (en) 2004-12-02
HK1085466A1 (en) 2006-08-25
HRP20090394T1 (en) 2009-08-31
DE602004021250D1 (de) 2009-07-09
PL378867A1 (pl) 2006-05-29
ATE432282T1 (de) 2009-06-15
ZA200508489B (en) 2007-04-25
US6897217B2 (en) 2005-05-24
NO20055510D0 (no) 2005-11-22
KR20060005379A (ko) 2006-01-17
RU2005136166A (ru) 2006-06-10
ECSP056115A (es) 2006-03-01
CN100503609C (zh) 2009-06-24
NO20055510L (no) 2006-01-20
ES2326270T3 (es) 2009-10-06
RU2373210C2 (ru) 2009-11-20
BRPI0409787A (pt) 2006-05-30
TW200427689A (en) 2004-12-16
PT1622912E (pt) 2009-08-17
JP2006523619A (ja) 2006-10-19
AR044041A1 (es) 2005-08-24
PE20050141A1 (es) 2005-04-01
CY1109263T1 (el) 2014-07-02
EP1622912B1 (en) 2009-05-27
US20040220194A1 (en) 2004-11-04
TWI355381B (en) 2012-01-01
BRPI0409787B1 (pt) 2018-08-21
AU2004233334B2 (en) 2010-08-12
WO2004094431A2 (en) 2004-11-04
IL171567A (en) 2013-01-31
BRPI0409787B8 (pt) 2021-05-25
KR100831107B1 (ko) 2008-05-20
CN1777609A (zh) 2006-05-24
TW201144317A (en) 2011-12-16
JP4527712B2 (ja) 2010-08-18
AU2004233334A1 (en) 2004-11-04
CL2004000847A1 (es) 2005-03-11
TWI375677B (en) 2012-11-01
US7368449B2 (en) 2008-05-06
CA2522813A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
NO332182B1 (no) 2-alkynyl- og 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidin-adenosin A2a-reseptorantagonist, anvendelse derav for fremstilling av et medikament, og farmasoytisk preparat omfattende forbindelsen
US11279713B2 (en) Heterocyclic compound and use thereof
JP4938348B2 (ja) アデノシンa2aレセプターアンタゴニスト
US7709492B2 (en) Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
US9527807B2 (en) Sulfonamide derivative and use thereof
JP4429724B2 (ja) [1,2,4]−トリアゾール二環式アデノシンA2aレセプタアンタゴニスト
NZ561414A (en) Method and composition for treating peripheral vascular diseases
JP2008521771A (ja) 改良された抗精神病活性および抗不安症活性を有するイソキサゾリン−インドール誘導体
JP2007507533A (ja) 肥満および関連障害の処置のための、選択的メラニン凝集ホルモンレセプターアンタゴニストとしてのアミノベンズイミダゾール
WO2005063697A2 (en) Substituted n-aryl amidines as selective d1 dopamine receptor antagonists for the treatment of obesity and cns disorders
CZ2000947A3 (cs) Substituované chromanové deriváty

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MM1K Lapsed by not paying the annual fees